Allon Therapeutics Inc.
NPCUF
$0.0001
$0.000.00%
OTC PK
| 03/31/2013 | 12/31/2012 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -40.26% | 36.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -66.83% | 67.65% | |||
| Operating Income | 66.83% | -67.65% | |||
| Income Before Tax | 85.05% | -282.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 85.05% | -282.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 85.05% | -282.54% | |||
| EBIT | 66.83% | -67.65% | |||
| EBITDA | 65.67% | -73.69% | |||
| EPS Basic | 85.15% | -282.58% | |||
| Normalized Basic EPS | 66.19% | -67.47% | |||
| EPS Diluted | 85.15% | -282.58% | |||
| Normalized Diluted EPS | 66.19% | -67.47% | |||
| Average Basic Shares Outstanding | 0.18% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.18% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||